Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given written consent to participate.
• Adults aged 18 years or older.
• People who have been diagnosed (through laboratory testing of tumor tissue) with a solid tumor cancer that has spread or cannot be surgically removed, and whose tumor has a specific genetic change called KRAS G12D mutation.
• People who are able to provide a stored tumor tissue sample or are willing to have a tumor biopsy taken before treatment begins.
• People whose cancer has at least one measurable area that can be tracked on scans, according to standard measurement guidelines.
• People who are expected to live for more than 3 months.
• People who are generally well enough to carry out everyday activities with no or only minor limitations, as rated on a standard medical scale (confirm with trial site).
• People whose bone marrow, liver, and kidneys are functioning adequately, as shown by blood tests.
• People who are able to meet the trial's specific requirements around contraception.
• People who have completed the required waiting periods after previous treatments, as specified in the trial protocol.

Who may not be able to join:

• People who have had certain side effects from previous treatments within the 28 days before starting the study.
• People who have a second, separate cancer diagnosis.
• People who have a known allergy or sensitivity to the study drug or any of its ingredients.
• People who have previously been treated with a targeted therapy that specifically targets the KRAS G12D mutation, or with a broader RAS-targeting therapy for this mutation.
• People who have had major surgery within 28 days before the first dose of the study drug.
• People who have cancer that has spread to the brain or the lining around the brain, and are experiencing symptoms from this.
• People who have other serious ongoing health conditions, as assessed by the doctor running the trial.
• People who have significant heart or blood vessel disease, as defined by the trial protocol (confirm with trial site).
• People who have an abnormally prolonged measurement on a heart tracing (ECG) known as the QTcF interval.
• People who are short of breath while at rest due to their cancer, or who need ongoing oxygen therapy for any medical reason.
• People who have active tuberculosis (TB) affecting the lungs.
• People who have a known history of a condition called interstitial lung disease, which involves scarring or inflammation in the lungs.
• People who have previously had an organ transplant or a stem cell transplant from another person.
• People who have had a serious infection within 28 days before the first dose of the study drug.
• People who have a condition affecting their immune system, whether present from birth or developed over time.
• People who are pregnant or breastfeeding.
• People who have other health conditions or circumstances that the trial doctor believes could interfere with following the trial procedures.
• People who are unwilling or unable to follow the procedures required by the trial.

Important: Always verify eligibility with the trial site directly before applying.